Puma Biotechnology (NASDAQ:PBYI) Stock Crosses Above 200 Day Moving Average - Time to Sell?

Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $3.19 and traded as high as $3.36. Puma Biotechnology shares last traded at $3.18, with a volume of 323,932 shares trading hands.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised shares of Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a research report on Thursday, May 22nd.

Puma Biotechnology Price Performance

The company has a market cap of $152.36 million, a P/E ratio of 3.99 and a beta of 1.30. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.43 and a current ratio of 1.53. The firm's fifty day moving average is $3.42 and its two-hundred day moving average is $3.19.

Insider Buying and Selling at Puma Biotechnology

In other Puma Biotechnology news, Director Allison Dorval sold 11,610 shares of the stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $3.40, for a total transaction of $39,474.00. Following the completion of the transaction, the director owned 75,390 shares of the company's stock, valued at $256,326. This represents a 13.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Alan H. Auerbach sold 25,592 shares of the company's stock in a transaction dated Tuesday, July 8th. The shares were sold at an average price of $3.53, for a total transaction of $90,339.76. Following the sale, the chief executive officer owned 7,202,481 shares in the company, valued at $25,424,757.93. This represents a 0.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 173,649 shares of company stock worth $596,914. Insiders own 23.30% of the company's stock.

Institutional Trading of Puma Biotechnology

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC raised its position in Puma Biotechnology by 167.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 10,137 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 6,351 shares during the period. CWM LLC raised its stake in shares of Puma Biotechnology by 214.1% during the second quarter. CWM LLC now owns 9,462 shares of the biopharmaceutical company's stock valued at $32,000 after acquiring an additional 6,450 shares in the last quarter. Graham Capital Management L.P. bought a new stake in shares of Puma Biotechnology during the fourth quarter valued at approximately $33,000. ProShare Advisors LLC bought a new stake in shares of Puma Biotechnology during the fourth quarter valued at approximately $36,000. Finally, Causeway Capital Management LLC bought a new stake in shares of Puma Biotechnology during the first quarter valued at approximately $42,000. 61.29% of the stock is owned by hedge funds and other institutional investors.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.